chartexchange

AHA26: Orforglipron outpaces oral semaglutide on predicted cardiovascular risk

Clinical Trials Arena | Nov 11, 2026 3:41 PM EST

GlobalData expects Eli Lilly to pair this CV risk data with orforglipron’s dosing convenience to differentiate it from oral semaglutide.
The post AHA26: Orforglipron outpaces oral semaglutide on predicted cardiovascular risk appeared first on Clinical Trials Arena .

Read original article